Unknown

Dataset Information

0

A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.


ABSTRACT: Human DNA topoisomerase I (hTop1p) catalyzes the relaxation of supercoiled DNA and constitutes the cellular target of the antitumor drug camptothecin (CPT). The X-ray crystal structure of the enzyme covalently joined to DNA and bound to the CPT analog Topotecan suggests that there are two classes of mutations that can produce a CPT-resistant enzyme. The first class includes changes in residues that directly interact with the drug, whereas a second class alters interactions with the DNA and thereby destabilizes the drug binding site. The Thr729Ala, that is part of a hydrophobic pocket in the enzyme C-terminal domain, belongs to a third group of mutations that confer CPT resistance, but do not interact directly with the drug or the DNA. To understand the contribution of this residue in drug resistance, we have studied the effect on hTop1p catalysis and CPT sensitivity of four different substitutions in the Thr729 position (Thr729Ala, Thr729Glu, Thr729Lys and Thr729Pro). Tht729Glu and Thr729Lys mutants show severe CPT resistance and furthermore, Thr729Glu shows a remarkable defect in DNA binding. We postulate that the maintenance of the hydrophobic pocket integrity, where Thr729 is positioned, is crucial for drug sensitivity and DNA binding.

SUBMITTER: Losasso C 

PROVIDER: S-EPMC2553582 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.

Losasso Carmen C   Cretaio Erica E   Fiorani Paola P   D'Annessa Ilda I   Chillemi Giovanni G   Benedetti Piero P  

Nucleic acids research 20080904 17


Human DNA topoisomerase I (hTop1p) catalyzes the relaxation of supercoiled DNA and constitutes the cellular target of the antitumor drug camptothecin (CPT). The X-ray crystal structure of the enzyme covalently joined to DNA and bound to the CPT analog Topotecan suggests that there are two classes of mutations that can produce a CPT-resistant enzyme. The first class includes changes in residues that directly interact with the drug, whereas a second class alters interactions with the DNA and there  ...[more]

Similar Datasets

| S-EPMC4089885 | biostudies-literature
| S-EPMC7251655 | biostudies-literature
| S-EPMC9094055 | biostudies-literature
| S-EPMC33414 | biostudies-literature
| S-EPMC2886027 | biostudies-literature
| S-EPMC6396120 | biostudies-literature
| S-EPMC2716488 | biostudies-literature
| S-EPMC7304410 | biostudies-literature
| S-EPMC3077681 | biostudies-literature
| S-EPMC9090595 | biostudies-literature